维普中文期刊产品整合服务
34篇 您的检索式:作者名="Man CH"
    题名 作者 年代 出处 被引量
1美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病源性轻度认知障碍诊断标准推荐显示文摘美国国立老化研究所(NIA)和阿尔茨海默病协会(ADA)组织了一个工作组,负责阿尔茨海默病(AD)痴呆前症状阶段——即本文所称的AD源性轻度认知障碍(MCI)的诊断标准的制订及完善。该工作组制订了以下两套标准:(1)在缺乏相应条件进行先进影像技术及脑脊液检查时,医务人员适用的核心临床标准;(2)适用于包括临床试验在内的科学研究的研究标准。后者纳入了基于影像技术及脑脊液检查的生物标志物的应用。并根据所出现的生物标志物的性质,将最终MCI诊断的确定性程度分为4个级别。而要使生物标志物有效应用于诊断,并在社区医疗服务中规范使用,尚需做大量的工作。McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly JJ Mayeux R Mohs RC Morris JC Rossor MN Schehens P Carrillo MC Thies B Weintraub S Phelps CH 贾建平(译) 陆璐(译) 张逸驰(译) 黄丽黄(译) 礼媛(译) 2012中华神经科杂志2012,45,5:51
2美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病痴呆诊断标准的推荐显示文摘由美国国立老化研究所(NIA)和阿尔茨海默病(AD)协会组织了一个工作组,负责修订1984年版AD痴呆的诊断标准。旨在确保修订后的标准具有足够的灵活性,既可供缺乏神经心理学测验、先进的影像技术和脑脊液检查措施的普通医务人员使用,也可供具备上述措施的科研、临床试验的专业研究者使用。新的标准广泛适用于各种原因的痴呆以及专门针对AD痴呆的标准,保留了1984年版标准中的“很可能的AD痴呆”的总体框架。在过去27年的经验基础上,工作组对临床诊断标准做了一些修改,保留了“可能的AD痴呆”的术语,但对其进行了更有针对性的重新定义。在科研用的“很可能的和可能的AD痴呆”的诊断标准中纳入了生物标志物证据。AD痴呆的核心临床标准仍将是临床实践中诊断的基础,但用生物标志物证据来提高AD痴呆诊断的病理生理学特异性也被人们寄予厚望。要实现AD痴呆的生物标志物诊断,还有许多工作摆在面前。McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly J J Mayeux R Mohs RC Morris JC Rossor MN Scheltens P Carrillo MC Thies B Weintraub S Phelps CH 贾建平(译) 陆璐(译) 张逸驰(译) 黄丽(译) 韩阅(译) 2012中华神经科杂志2012,45,5:52
3Endophthalmitis after keratoprosthesis: Incidence, bac- terial causes, and risk factors 显示文摘Nouri M Terada H Alfonso EC Foster CS Durand ML Dohl- man CH 2001Arch Ophthcdmol2001,119,4:1
4FLT3 inhibition:a moving and evolving target in acute myeloid leukaemia显示文摘Leung AY Man CH Kwong YL 2013Leukemia2013,27,2:1
5Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia显示文摘He BL Shi X Man CH 2014Blood2014,123,16:1
6Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation显示文摘Man CH Fung TK Ho C 2012Blood2012,119,22:1
7A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML显示文摘Man CH Lam SS Sun MK 2014Blood2014,123,16:1
8Visible-light-driven photocatalyst of Bi2 WO6 nanoparticles prepared via amor- phous complex precursor and photocatalytic properties 显示文摘ZHANG SH C ZHANG CH MAN Y 2006J Solid State Chem2006,179,:1
9Sorafenib treatment of FLT3-ITD(+)acute myeloid leukemia:favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation显示文摘Man CH Fung TK Ho C 2012Blood2012,119,22:1
10Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory 显示文摘 Takamiya K Han JS Man H Kim CH Rumbaugh G Yu S Ding L He C Petralia RS Wenthold RJ Gallagher M Huganir RL 2003Cell2003,112,5:1
11Sorafenib treatment of FLT3-ITD (+)acute leukemia:favorable initial outcome and mechanisms of subsequent non responsiveness asso- ciated with the emergence of a D835 mutation 显示文摘Man CH Fung TK Ho C 2012Blood2012,119,6:1
12Acquired muhicellular-mediated resistance to alkylating agents in cancer 显示文摘Kobayashi H Man S Graham CH Kapitain SJ Teicher BA Kerbel RS 1993Proc Natl Acad Sci USA1993,90,8:1
13Sorafcnib treatment of FH3- ITD( + ) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation 显示文摘Man CH Fung TK Ho C 2012Blood2012,119,22:1
14Acquired multicellular-mediated resistance to alkylating agents in cancer 显示文摘Kobayashi H Man S Graham CH 1993Proc Natl Acad Sci USA1993,90,8:1
15Bringing an old drug to a new treatment strategy in treating FLT-ITD AML-combination of homoharringtonine and serafenib 显示文摘Ho ESK Lain SSY Man CH 2014Blood ( ASH annual meeting Abstracts )2014,124,21:1
16ITD ( + ) acute myeloid leukemia Sorafenib treatment of FLT3- favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation显示文摘Man CH Fung TK Ho C 2012Blood2012,119,22:1
17A pilot study to examine the feasibility and effects of a home- based aerobic program on reducing fatigue in children with acute lymphoblastic leukenfia显示文摘Yeh CH Man WJ Lin US 2011Cancer Nurs2011,34,1:1
18FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia 显示文摘Leung AY Man CH Kwong YL 2013Leukemia2013,27,2:1
19Composite auditory evoked potential index versus bispectral index to estimate the level of sedation in paralyzed critically ill patients: a prospective observational study显示文摘Lu CH Man KM Ou-Yang HY 2008Anesth Analg2008,107,4:1
20Paraquat positioning:findings on chest radiography and CT in 42 patients显示文摘Jung LM Kyung SL Man CH 1991A JR1991,157,4:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费